Akiko Sarashina

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study

Ryuzo Kawamori, Nobuya Inagaki, Eiichi Araki et al. · Diabetes Obesity and Metabolism · 2011 · 112 citations

Medicine, Pharmacology, Pharmacotherapy +15

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Isamu Okamoto, Hiroyasu Kaneda, Taroh Satoh et al. · Molecular Cancer Therapeutics · 2010 · 94 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

Akiko Sarashina, Kazuki Koiwai, Leo Seman et al. · Drug Metabolism and Pharmacokinetics · 2012 · 86 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)

Haruyasu Murakami, Tomohide Tamura, Toshiaki Takahashi et al. · Cancer Chemotherapy and Pharmacology · 2011 · 85 citations

Medicine, Oncology, Pharmacology +9

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

Akiko Sarashina, Shogo Sesoko, Mitsuyoshi Nakashima et al. · Clinical Therapeutics · 2010 · 59 citations

Medicine, Endocrinology, Pharmacology +13